KPV
A tripeptide studied for gut health and inflammation control.
Overview
KPV (lysine-proline-valine) is a short tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH). It is studied for strong anti-inflammatory properties, particularly in the gut, and has become a favorite for gut-health and anti-inflammatory research protocols.
Dosing
Oral
- Starting dose
- 500 mcg
- Common dose
- 1–5 mg
- Frequency
- 1–2× daily
- Notes
- Gut-focused protocols; capsules or sublingual.
Injection
- Starting dose
- 500 mcg
- Common dose
- 1–2 mg
- Frequency
- 1× daily
- Notes
- SubQ; typically cycled.
Reported research/reference doses for educational purposes only. Always verify against primary literature and applicable regulations. Not medical advice.
How it works
KPV inhibits the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, and promotes anti-inflammatory signaling. In the gut, it supports mucosal healing and modulates immune responses, making it a focus of inflammatory bowel disease research.
Common research uses
- Inflammatory bowel disease research
- Gut mucosal healing and gut health
- Anti-inflammatory cytokine modulation
- Skin inflammation studies (topical)
Considerations
Research compound. Human data are limited; most evidence is preclinical. Injectable handling requires care. Research use only.